Waldenstrom Macroglobulinemia clinical trials at UC Cancer

• A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies

  open to eligible people ages 18 years and up

  This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of VLS-101, an antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells. The study is evaluating VLS-101 in patients with previously treated hematological cancers.

  at UCLA UCSD

• A Study of ARQ 531 in Patients With Selected Hematologic Malignancies

  open to eligible people ages 18 years and up

  This is an open-label, multi-center Phase 1/2 study of ARQ 531 in patients with selected hematologic malignancies.

  at UCLA

• A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

  open to eligible people ages 18 years and up

  This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.

  at UCSF

• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

  open to eligible people ages 18 years and up

  This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.

  at UC Irvine UCSD

Last updated: October 12, 2020